Bio & Healthcare Industry (바이오·헬스케어): The Next Export Powerhouse

South Korea is the world's largest contract manufacturer of biopharmaceutical products — a position it reached in less than 15 years. Samsung Biologics, the company that didn't exist until 2011, is now the world's single largest biopharmaceutical contract manufacturer by capacity. This is not a future ambition; it is a present reality. Korea's bio and healthcare industry generated approximately $16 billion in exports in 2023, and the government has targeted it as the country's next trillion-dollar export sector after semiconductors.

바이오의약품 위탁생산 (Biopharmaceutical Contract Manufacturing)

삼성바이오로직스 (Samsung Biologics)

삼성바이오로직스 (Samsung Biologics) was established in 2011 as a joint venture between Samsung and Quintiles (now IQVIA). It operates on Songdo International Business District in 인천 (Incheon).

Its growth has been extraordinary:

At 604,000 liters of bioreactor capacity (2023), Samsung Biologics operates the world's single largest biopharmaceutical manufacturing facility by capacity. Its 5th plant, currently under construction, will bring total capacity to 784,000 liters — further extending its lead.

Clients include Pfizer, Roche, AstraZeneca, Bristol-Myers Squibb, Moderna and most of the world's major biopharmaceutical companies.

셀트리온 (Celltrion)

셀트리온 is Korea's pioneering biosimilar company — producing biologically similar versions of branded biopharmaceutical products whose patents have expired.

Its flagship product — 램시마 (Remsima), a biosimilar to Janssen's 레미케이드 (Remicade, infliximab) — was the world's first monoclonal antibody biosimilar approved in the European Union (2013) and the United States (2016). Remsima's approval was a landmark event in global pharmaceutical history — demonstrating that complex biological drugs could be successfully replicated and approved.

Celltrion's biosimilar portfolio has expanded to include products targeting cancer, autoimmune diseases, and other major indications.

글로벌 CMO 시장 점유율 (Global biopharmaceutical CMO market):

Tip — 바이오와 반도체의 공통점 (What bio and semiconductors have in common): The Korean government and industry deliberately use the semiconductor development model as a template for biotech. Both require: massive upfront capital investment, years before profitability; precision manufacturing at microscopic scale; a quality and reliability track record that takes time to establish; and the trust of global companies who cannot afford failures in their supply chain. Samsung Biologics' rapid growth replicated Samsung Electronics' semiconductor playbook almost exactly — invest aggressively in capacity, underprice competitors to build market share, then leverage scale and quality to move upmarket.

코로나19와 한국 바이오 (COVID-19 and Korean Bio)

The COVID-19 pandemic accelerated Korea's bio industry trajectory dramatically. Korea became a major vaccine contract manufacturing hub during the pandemic:

• 삼성바이오로직스: Produced Moderna mRNA vaccine drug substance for global distribution

• SK바이오사이언스 (SK Bioscience): Manufactured AstraZeneca's COVID-19 vaccine under license; also developed its own vaccine 스카이코비원 (SKYCovione) — the first Korean-developed COVID-19 vaccine, approved in 2022

The pandemic demonstrated Korea's manufacturing reliability under extreme conditions — a credential that has accelerated subsequent business development.

의료기기 (Medical Devices)

Korea's medical device industry generated approximately $7 billion in exports in 2023 — the 5th largest globally.

Key segments:

• 체외진단기기 (In-vitro diagnostics): Korea became a globally recognized supplier of COVID-19 test kits — companies including 씨젠 (Seegene) supplied test kits to over 100 countries

• 초음파 진단기기 (Ultrasound equipment): 삼성메디슨 (Samsung Medison) is a globally significant ultrasound equipment manufacturer

• 디지털 헬스케어 (Digital healthcare): Korea's IT infrastructure and healthcare data ecosystem position it as an emerging center for AI-based medical diagnostics

한국의 의료 시스템 (Korea's Healthcare System)

Korea's domestic healthcare system is itself a global reference point:

• 건강보험 보장률 (National health insurance coverage): 98% of the population covered under the 국민건강보험 (National Health Insurance) system

• 기대수명 (Life expectancy): 83.6년 (2022) — among the highest in the OECD

• MRI·CT 보유 (MRI and CT availability): Korea has among the highest per-capita availability of MRI and CT scanners in the OECD

• 의료 관광 (Medical tourism): Korea received approximately 500,000 medical tourists in 2023 — primarily for cosmetic surgery, cancer treatment, and health checkups; medical tourism revenue approximately $1 billion

Key Facts

다음 아티클: Korea Builds the World (해외건설): From Middle East to Megaprojects →